2009;158:177 84. 666. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163 70. 667. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular- weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med. 2007;167:2423 30. 668. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin- induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57: 177 84. 669. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocy- topenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15: 611 6. 670. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31:561 72. 671. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995;332:1374 6. 672. Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. J Am Coll Cardiol. 1998;31:1449 59. 673. Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfrac- tionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA. 2010;304:1339 49. 674. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152: 887.e9 887.e14. 675. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine admin- istered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51:27 31. 676. 